References
- Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Mathews TJ. Births: final data for 2006. National vital statistics reports. Vol 57. No. 7. Hyattsville, MD: National Center for Health Statistics; 2009.
- Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265–274.
- Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW. Prevention of recurrent preterm delivery by 17-α-hydroxyprogesterone caproate. N Eng J Med 2003;348:2379–2385.
- Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273–279.
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion, Number 291. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115–1116.
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion, Number 419. Use of progesterone to reduce preterm birth. Obstet Gynecol 2008;112:963–965.
- Meis PJ. 17 Hydroxyprogesterone for the prevention of preterm delivery. Obstet Gynecol 2005;105;1128–1135.
- da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–424.
- Johnstone EE, Franklin RR. Assay of progestins for fetal virilizing properties using the mouse. Obstet Gynecol 1964;23:359–362.
- Courtney KD, Valerio DA. Teratology in the Macaca mulatta.Teratology 1968;1:163–72.
- Carbone JP, Brent RL. Genital and nongenital teratogenesis of prenatal progesterone therapy: the effects of 17α-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6L mouse. Am J Obstet Gynecol 1993;169:1292–1298.
- Miller RE, Nelson GW, Johnson CK. Evaluation of teratogenic potential of Delalutin, (17 α-hydroxyprogesterone caproate) in mice. Teratology 1983;28:201–208.
- Ness A, Dias T, Damus K, Burd I, Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 2006;195:1174–1179.
- Papiernik-Berkhauer E. Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature. Edition Schering Serie IV 1970;3:65–68. ik.